Agenus | AGEN - Current Assets


Agenus reported $95.28M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Agenus USD 95.28M 38.15M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Celldex Therapeutics USD 459.22M 75.44M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 59.77B 601M Jun/2026
Jiangsu Hengrui CNY 52.04B 553.82M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 182.52M 37.42M Mar/2026
Merck EUR 14.16B 932M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Northwest Biotherapeutics USD 7.2M 1.04M Sep/2025
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 522.17M 33.8M Mar/2026